Adjuvant aromatase inhibitor therapy: Outcomes and safety
- 31 May 2010
- journal article
- review article
- Published by Elsevier BV in Cancer Treatment Reviews
- Vol. 36 (3), 249-261
- https://doi.org/10.1016/j.ctrv.2009.12.010
Abstract
No abstract availableKeywords
This publication has 87 references indexed in Scilit:
- Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast CancerThe New England Journal of Medicine, 2009
- Extending the benefits of adjuvant therapy in early HR+ breast cancerBreast Cancer Research and Treatment, 2008
- Practical guidance for the management of aromatase inhibitor-associated bone lossAnnals of Oncology, 2008
- Competing Causes of Death From a Randomized Trial of Extended Adjuvant Endocrine Therapy for Breast CancerJNCI Journal of the National Cancer Institute, 2008
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trialThe Lancet Oncology, 2008
- Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancerMenopause, 2007
- Diffusion of aromatase inhibitors for breast cancer therapy between 1996 and 2003 in the Cancer Research NetworkBreast Cancer Research and Treatment, 2007
- Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialThe Lancet, 2007
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005
- Aromatase Inhibitors: Current Indications and Future Prospects for Treatment of Postmenopausal Breast CancerJournal of the American Geriatrics Society, 2004